8-KItem 2.02 · Results of OperationsItem 5.02 · Officer/Director ChangeItem 8.01 · Other EventsItem 9.01 · Financial Statements

Michael R.

Filed with the SEC on · Summarized by InvestorsBot

Michael R. McDonnell appointed to Baxter’s Board and Audit Committee (appointed Feb 10, effective Feb 13, 2026). Former CFO of Biogen (Aug 2020–Feb 2025) and IQVIA (Dec 2015–Jul 2020); serves on Merit Medical board. $BAX 📌 #BoardUpdate #Healthcare

McDonnell will be paid under Baxter’s non‑employee director plan, eligible for Directors’ Deferred Compensation Plan, and will receive prorated equity awards for Feb 13–2026 annual meeting. No related‑party transactions disclosed. $BAX 💼 #Governance #Compensation

Cathy R. Smith and Stephen H. Rusckowski resigned from Baxter’s Board and committees effective Feb 13, 2026; neither resignation was due to disagreement. Patricia B. Morrison becomes chair of the Nominating, Corporate Governance & Public Policy Committee. $BAX 🔽 #Board #Governance

Read the original filing on SEC EDGAR

Get summaries like this in your inbox every morning

Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.

Subscribe free

More from BAXTER INTERNATIONAL INC